MX2012006829A - Formulaciones resistentes al abuso. - Google Patents

Formulaciones resistentes al abuso.

Info

Publication number
MX2012006829A
MX2012006829A MX2012006829A MX2012006829A MX2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A
Authority
MX
Mexico
Prior art keywords
dosage form
abuse
hydromorphone
resistant formulations
sustained
Prior art date
Application number
MX2012006829A
Other languages
English (en)
Other versions
MX348361B (es
Inventor
Ehab Hamed
Manuel A Vega Zepeda
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2012006829A publication Critical patent/MX2012006829A/es
Publication of MX348361B publication Critical patent/MX348361B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

Esta revelación se refiere a una forma farmacéutica oral de liberación sostenida para la administración de una vez al día que comprende una matriz que contiene un modificador de la viscosidad y gránulos revestidos que contienen hidromorfona. La forma farmacéutica puede tener un perfil de liberación de modo tal que 16 horas después de la administración, se libera menos de alrededor de 85 por ciento de la hidromorfona. Además, la forma farmacéutica puede tener resistencia al alcohol y/o a la trituración.
MX2012006829A 2009-12-17 2010-12-16 Formulaciones resistentes al abuso. MX348361B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751509P 2009-12-17 2009-12-17
PCT/US2010/060755 WO2011084593A2 (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Publications (2)

Publication Number Publication Date
MX2012006829A true MX2012006829A (es) 2012-07-10
MX348361B MX348361B (es) 2017-06-07

Family

ID=43618139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006829A MX348361B (es) 2009-12-17 2010-12-16 Formulaciones resistentes al abuso.

Country Status (10)

Country Link
US (2) US20120225122A1 (es)
EP (1) EP2512456A2 (es)
JP (1) JP5894717B2 (es)
CN (1) CN102665694A (es)
AU (1) AU2010339882B2 (es)
CA (1) CA2784407A1 (es)
IL (1) IL219961A (es)
MX (1) MX348361B (es)
NZ (1) NZ600640A (es)
WO (1) WO2011084593A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US9456766B2 (en) 2007-11-26 2016-10-04 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
JP5452500B2 (ja) 2007-11-26 2014-03-26 シー・アール・バード・インコーポレーテッド カテーテルの血管内留置のための統合システム
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
JP5795576B2 (ja) 2009-06-12 2015-10-14 バード・アクセス・システムズ，インコーポレーテッド 心電図（ｅｃｇ）信号を使用して心臓内またはその近くに血管内デバイスを位置決めするコンピュータベースの医療機器の作動方法
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
WO2011019760A2 (en) 2009-08-10 2011-02-17 Romedex International Srl Devices and methods for endovascular electrography
EP2517622A3 (en) 2009-09-29 2013-04-24 C. R. Bard, Inc. Stylets for use with apparatus for intravascular placement of a catheter
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
BR112012019354B1 (pt) 2010-02-02 2021-09-08 C.R.Bard, Inc Método para localização de um dispositivo médico implantável
CA2800813C (en) 2010-05-28 2019-10-29 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
AU2011289513B2 (en) 2010-08-09 2014-05-29 C.R. Bard, Inc. Support and cover structures for an ultrasound probe head
WO2012024577A2 (en) 2010-08-20 2012-02-23 C.R. Bard, Inc. Reconfirmation of ecg-assisted catheter tip placement
WO2012058461A1 (en) 2010-10-29 2012-05-03 C.R.Bard, Inc. Bioimpedance-assisted placement of a medical device
CN105662402B (zh) 2011-07-06 2019-06-18 C·R·巴德股份有限公司 用于插入引导系统的针长度确定和校准
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
WO2013158638A1 (en) * 2012-04-17 2013-10-24 Mylan, Inc. Stable dosage forms of skeletal muscle relaxants with extended release coating
CN104837413B (zh) 2012-06-15 2018-09-11 C·R·巴德股份有限公司 检测超声探测器上可移除帽的装置及方法
BR112015004190A2 (pt) * 2012-09-03 2017-07-04 Daiichi Sankyo Co Ltd composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2811323T3 (es) 2014-02-06 2021-03-11 Bard Inc C R Sistemas para el guiado y la colocación de un dispositivo intravascular
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3852622A1 (en) 2018-10-16 2021-07-28 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP5259183B2 (ja) * 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用に対して保護された経口剤形
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
MX336861B (es) * 2007-09-13 2016-02-04 Cima Labs Inc Formulacion de farmaco resistente al abuso.
PT2057984E (pt) * 2007-11-09 2010-03-10 Acino Pharma Ag Comprimidos retard com hidromorfona
US8927025B2 (en) * 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms

Also Published As

Publication number Publication date
WO2011084593A3 (en) 2012-03-29
US20140294953A1 (en) 2014-10-02
CN102665694A (zh) 2012-09-12
AU2010339882A1 (en) 2012-07-05
EP2512456A2 (en) 2012-10-24
US9474721B2 (en) 2016-10-25
AU2010339882B2 (en) 2016-10-27
JP2013514386A (ja) 2013-04-25
NZ600640A (en) 2014-11-28
CA2784407A1 (en) 2011-07-14
JP5894717B2 (ja) 2016-03-30
MX348361B (es) 2017-06-07
IL219961A (en) 2017-06-29
IL219961A0 (en) 2012-07-31
WO2011084593A2 (en) 2011-07-14
US20120225122A1 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
NZ600640A (en) Abuse-resistant formulations
MX347753B (es) Formulaciones resistentes al abuso.
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
WO2008135527A3 (en) Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
MX2007009162A (es) Formas de dosis rsistente al alcohol.
MX2012013021A (es) Formulaciones resistentes a alcohol.
NZ610701A (en) Once daily formulation of lacosamide
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MX343358B (es) Tabletas de acetato de ulipristal.
MX336038B (es) Composiciones farmaceuticas de liberacion controlada de tapentadol.
TW200621317A (en) Pharmaceutical composition
MX2009004439A (es) Composicion de ibuprofeno.
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
WO2011104652A3 (en) Veterinary compositions
UA103179C2 (ru) Фармацевтическая композиция, которая содержит эзетимиб
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
IL203433A (en) Process for Preparing Pharmaceutical and Solid Release Controlled Compositions Containing Oxacarbazapine
WO2009019662A3 (en) Oral metaxalone compositions
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
GB2495563A (en) Co-processed excipient compositions

Legal Events

Date Code Title Description
FG Grant or registration